Covid19, Hematologic Malignancy, Vaccine Response Impaired
Conditions
Brief summary
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can lead to fatal pneumonia associated with high rates of hospitalization in intensive care units (ICU). Hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs. 8%). The severity of Covid-19 may be related to their treatment, in particular anti-CD20 used in B lymphoid hemopathies. In fact, anti-CD20 antibodies induce rapid and prolonged depletion of B cells, but they are necessary for development. humoral immune responses. But currently, no immunogenicity data are known for patients with hemopathy or in those on anti-lymphocyte immunochemotherapy.
Detailed description
The aim of this study is to evaluate the humoral response after vaccination against SARS-CoV-2 in a French multicenter cohort of patients with hemopathies. Analysis of hemopathies and immunochemotherapy subgroups will determine whether there is a need to strengthen immunization schedules. In addition, the study wish to assess the safety and clinical efficacy of mRNA vaccines in this cohort.
Interventions
OTHERPatients with hemopathy
optimal humoral response at 1 month after COVID-19 vaccination
Sponsors
Centre Hospitalier de Cornouaille
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Benign or malignant hemopathy * With priority vaccination indication * Having benefited from anti-covid-19 mRNA vaccination
Exclusion criteria
* Patients under legal protection * Palliative care patients * History of known Covid-19 disease (\<1 year)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| humoral response after COVID19 vaccination | 1 month after vaccination | SARS-CoV-2 Trimeric S IgG titers (BAU/ml) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| humoral response after COVID19 vaccination | before first dose vaccination | SARS-CoV-2 Trimeric S IgG titers (BAU/ml) |
| clinical response after COVID19 vaccination | 12 months after vaccination | SARS-CoV-2 disease onset in the follow-up |
| security of mRNA COVID19 vaccine | 3 months after vaccination | side effects onset in the follow-up |
Countries
France
Outcome results
None listed